Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Average Recommendation of “Reduce” from Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received an average rating of “Reduce” from the six ratings firms that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $30.00.

Several brokerages recently commented on FMS. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Finally, Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently made changes to their positions in the company. TD Waterhouse Canada Inc. bought a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at about $36,000. Brooklyn Investment Group grew its stake in Fresenius Medical Care AG & Co. KGaA by 424.5% in the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock valued at $32,000 after acquiring an additional 1,040 shares during the period. CIBC Private Wealth Group LLC increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after acquiring an additional 1,103 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth approximately $43,000. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after purchasing an additional 1,768 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE FMS opened at $23.84 on Friday. The company has a market capitalization of $13.99 billion, a PE ratio of 19.54, a P/E/G ratio of 0.64 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $21.83 and a twelve month high of $30.46. The firm has a fifty day simple moving average of $25.56 and a 200 day simple moving average of $26.35.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The business had revenue of $5.73 billion for the quarter, compared to analysts’ expectations of $4.72 billion. On average, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.